Navigation Links
LifeQuest World Launches Immune System Boosting Supplement to the North American Market
Date:5/6/2008

LAS VEGAS, May 6 /PRNewswire-FirstCall/ -- LifeQuest World Corporation (OTC Bulletin Board: LQWC) is pleased to announce that after 7 months of preparatory work, ImmunXT, their Immune System enhancement supplement, has been released for sale to the North American Market as of March 2008. ImmunXT has been proclaimed as "the most powerful natural immune stimulatory supplement ever discovered". ImmunXT (US Patent #7,205,284 B2) is a bio-active Micro-algae Complex extracted from Spirulina. Clinically tested at The National Center for Natural Product Research at The University of Mississippi, and researched at The Johns Hopkins School of Medicine, ImmunXT has proven to be up to 1,000 times more active in stimulating significant Immune System responses than any other source available.

ImmunXT supports optimal immune function as it stimulates and boosts the early warning mechanism of the body's first line of defense. ImmunXT also enhances the accuracy of the appropriate immune response. This product has been shown to promote Natural Killer (NK) Cell production (whose role is to attack tumor cells and infected body cells), and also to help reduce inflammation throughout the body structure. ImmunXT is consumer safe and its ingredient source is completely natural and 100% vegetarian.

In a world where life threatening toxic elements, dangerous environmental pollutants, new potent viruses, drug-resistant bacteria and the constant threat of Pandemics, "Superbugs", chronic disease, allergies and food borne illnesses have become daily news headlines, LifeQuest is pleased to offer this powerful dietary supplement to support the immune system on a daily basis.

ImmunXT can be purchased online at http://www.lifequestworld.com.

About LifeQuest World Corporation Inc.

LifeQuest World Corporation Inc. is a life science company focused on the global commercialization of unique, patented and scientifically proven natural-source health products that allow for a proactive health management approach while delivering the highest levels of effectiveness and safety. LifeQuest's new, patented extract, developed by leading research scientists at the National Center for Natural Products Research (NCNPR) at the University of Mississippi, "... is one of the most promising projects our Center has produced in recent years, including its intellectual property," says Dr. Walter G. Chambliss, Director of Technology Management at the University of Mississippi. "Our research has shown that this extract is the most powerful, natural immune-stimulatory dietary supplement discovered to date with respect to macrophage activation," says Dr. David Pasco, Assistant Director at NCNPR. The results of this research were published in Planta Medica (Pugh et al, 2001 67(8): 737-742).

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products or actions in development are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this document may also contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.


'/>"/>
SOURCE LifeQuest World Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
4. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
5. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
6. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
7. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
8. PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso
9. Doping technique brings nanomechanical devices into the semiconductor world
10. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
11. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... , ... June 22, 2017 , ... ... leaders in designating infertility as a disease, bringing new hope for prospective parents ... their 2017 annual meeting to back the World Health Organization’s designation in hopes ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell ... the biopharma and life sciences industries, continue to be in demand for their ... Wolf will be speaking on “The State of Information Governance in the Biopharmaceutical ...
(Date:6/22/2017)... ... June 22, 2017 , ... RURO, Inc., ... Limfinity® version 6.5, a content-packed update to the Limfinity® framework. , LimitLIS® and ... and more diverse base of customers among labs and other businesses. Limfinity® 6.5 ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... CTNext board of directors has formed a Higher Education Entrepreneurship Advisory Committee to ... of institution presidents and other high-ranking representatives from 35 higher education institutions across ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):